Cargando…
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165862/ https://www.ncbi.nlm.nih.gov/pubmed/34104221 http://dx.doi.org/10.1177/17562864211020082 |
| _version_ | 1783701401383206912 |
|---|---|
| author | Achiron, Anat Mandel, Mathilda Dreyer-Alster, Sapir Harari, Gil Magalashvili, David Sonis, Polina Dolev, Mark Menascu, Shay Flechter, Shlomo Falb, Rina Gurevich, Michael |
| author_facet | Achiron, Anat Mandel, Mathilda Dreyer-Alster, Sapir Harari, Gil Magalashvili, David Sonis, Polina Dolev, Mark Menascu, Shay Flechter, Shlomo Falb, Rina Gurevich, Michael |
| author_sort | Achiron, Anat |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8165862 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81658622021-06-07 Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies Achiron, Anat Mandel, Mathilda Dreyer-Alster, Sapir Harari, Gil Magalashvili, David Sonis, Polina Dolev, Mark Menascu, Shay Flechter, Shlomo Falb, Rina Gurevich, Michael Ther Adv Neurol Disord Letter to the Editor SAGE Publications 2021-05-29 /pmc/articles/PMC8165862/ /pubmed/34104221 http://dx.doi.org/10.1177/17562864211020082 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Achiron, Anat Mandel, Mathilda Dreyer-Alster, Sapir Harari, Gil Magalashvili, David Sonis, Polina Dolev, Mark Menascu, Shay Flechter, Shlomo Falb, Rina Gurevich, Michael Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title | Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_full | Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_fullStr | Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_full_unstemmed | Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_short | Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| title_sort | author response to: correspondence to humoral immune response to covid-19 mrna vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165862/ https://www.ncbi.nlm.nih.gov/pubmed/34104221 http://dx.doi.org/10.1177/17562864211020082 |
| work_keys_str_mv | AT achironanat authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT mandelmathilda authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT dreyeralstersapir authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT hararigil authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT magalashvilidavid authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT sonispolina authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT dolevmark authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT menascushay authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT flechtershlomo authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT falbrina authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies AT gurevichmichael authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies |